Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status (Ascending)
55150-0305-10 55150-0305 Dexamethasone Sodium Phosphate Dexamethasone Sodium Phosphate 100.0 mg/10mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous June 7, 2019 In Use
71872-7239-01 71872-7239 Dexamethasone Sodium Phosphate Dexamethasone Sodium Phosphate 100.0 mg/10mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous Feb. 15, 2021 In Use
72865-0140-30 72865-0140 Dutasteride Dutasteride 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral March 9, 2020 In Use
72865-0140-90 72865-0140 Dutasteride Dutasteride 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral March 9, 2020 In Use
72578-0019-06 72578-0019 Dutasteride Dutasteride 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral April 15, 2019 In Use
72578-0019-16 72578-0019 Dutasteride Dutasteride 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral April 15, 2019 In Use
69539-0091-30 69539-0091 Erlotinib Hydrochloride Erlotinib Hydrochloride 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 11, 2021 In Use
69539-0092-30 69539-0092 Erlotinib Hydrochloride Erlotinib Hydrochloride 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 11, 2021 In Use
69539-0090-30 69539-0090 Erlotinib Hydrochloride Erlotinib Hydrochloride 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 11, 2021 In Use
72205-0081-30 72205-0081 Erlotinib Hydrochloride Erlotinib Hydrochloride 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 11, 2021 In Use
72205-0080-30 72205-0080 Erlotinib Hydrochloride Erlotinib Hydrochloride 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 11, 2021 In Use
72205-0082-30 72205-0082 Erlotinib Hydrochloride Erlotinib Hydrochloride 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 11, 2021 In Use
72485-0218-30 72485-0218 Erlotinib hydrochloride Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 6, 2019 In Use
72485-0219-30 72485-0219 Erlotinib hydrochloride Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 6, 2019 In Use
72485-0217-30 72485-0217 Erlotinib hydrochloride Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 6, 2019 In Use
50090-1704-00 50090-1704 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Feb. 18, 2015 In Use
50090-1704-01 50090-1704 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Aug. 7, 2018 In Use
50090-1704-02 50090-1704 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Feb. 18, 2015 In Use
70518-3019-00 70518-3019 Dexamethasone Sodium Phosphate Dexamethasone Sodium Phosphate 4.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intralesional, Intramuscular, Intravenous, Soft Tissue Feb. 8, 2021 In Use
70518-0397-00 70518-0397 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral April 4, 2017 In Use
70518-0397-01 70518-0397 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral April 4, 2017 In Use
70518-0397-02 70518-0397 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral May 11, 2018 In Use
69539-0181-01 69539-0181 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Feb. 10, 2020 In Use
72205-0054-01 72205-0054 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous May 12, 2020 In Use
69539-0034-01 69539-0034 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 5, 2019 In Use

Found 10,000 results in 2 milliseconds — Export these results